Clinical PET in Oncology.

Area of Science:

• Nuclear Medicine
• Oncology
• Medical Imaging

Background:

• Positron Emission Tomography (PET) is a key imaging modality in clinical oncology.
• Fluorodeoxyglucose (FDG) is the primary radiopharmaceutical used in oncologic PET scans.
• FDG-PET leverages the increased metabolic activity of malignant cells for detection.

Purpose of the Study:

• To review the established and emerging applications of FDG-PET in cancer detection and staging.
• To highlight the diagnostic accuracy and clinical utility of FDG-PET across various malignancies.
• To discuss the cost-effectiveness and reimbursement policies related to FDG-PET for specific indications.

Main Methods:

• Review of clinical applications and studies utilizing FDG-PET imaging in oncology.
• Analysis of FDG uptake patterns in relation to tumor grade and malignancy.
• Evaluation of whole-body imaging capabilities for disease distribution assessment.

Main Results:

• FDG-PET demonstrates high accuracy in diagnosing malignant solitary pulmonary nodules and staging lung cancer, with proven cost-effectiveness.
• Established utility in brain tumors, with preliminary data supporting its use in colorectal, breast, melanoma, lymphoma, head and neck, musculoskeletal, ovarian, pancreatic, and thyroid cancers.
• Whole-body PET imaging significantly enhances the documentation of malignancy distribution.

Conclusions:

• FDG-PET is a highly accurate and valuable tool for oncologic imaging, particularly in lung cancer.
• Its applications are expanding, showing promise in staging and detecting recurrence across a wide spectrum of cancers.
• Clinical adoption is supported by demonstrated accuracy, cost-effectiveness, and favorable reimbursement policies for key indications.